Sirona Biochem Begins Cell Preservation Research
Sirona Biochem (SBM:tsxv) Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia
– Momentum Public Relations – April 11, 2016
Sirona Biochem Corp. (SBM:tsxv) (ZSB:Frankfurt) (ZSB: Xetra) (the “Company“) announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds, produced by Sirona’s subsidiary TFChem, for use in the preservation of red blood cells (RBC) and other cell lines.
Studies will be performed to evaluate improvement in the quality of RBCs after hypothermic storage and cryopreservation. Further research is being planned which will involve tissue preservation for applications such as organ transplant. Initial testing will begin in May with results expected in Q4 2016.
“We are thrilled that a team led by Dr. Du will study our compounds in RBC preservation and that he has accepted a position on our Scientific Advisory Board. There is a global unmet need when it comes to storage/shelf life of these blood products,” said Dr. Howard Verrico, CEO.
“Extending the shelf life would greatly improve the ability to use donated blood. Current typical storage of donated blood is limited to 42 days. Extending this will have the potential to save lives at times of disaster, maintain supply of rare blood types and lessen overall blood inventory losses due to storage limitations. As a member of our Scientific Advisory Board, Dr. Du will be able to assist in research and development of multiple commercial indications for our new compounds,” he added.
About Dr. Du
Dr. Caigan Du is a scientist at the Vancouver Coastal Health Research Institute and an Associate Professor in the Department of Urologic Sciences at the University of British Columbia. He received a Ph.D. degree in Biochemistry in UK and postdoctoral training in Immunology in USA. He is interested in the pathogenesis of kidney ischemia-reperfusion injury and transplant rejection, and molecular control of urinary malignancies. He has been studying the impact of kidney donor-derived factors on renal allograft rejection, and the molecular pathways of kidney injury and regeneration in experimental models.
He is also interested in developing medical solution including drugs made from natural compounds for all kinds of health problems, including immune disorders, organ preservation, kidney failure and urinary cancer. He is the PI of many grant supports from the Kidney Foundation of Canada and the Canadian Institutes of Health Research.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information please visit www.sironabiochem.com.
- Published in Blog, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Selected to Present at BIO-Europe Spring
Sirona Biochem Selected to Present at BIO-Europe Spring
– Momentum Public Relations – March 21, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan Convention Center, Stockholm, Sweden.The main goals for the conference include: seeking strategic partnerships and investment from big pharma to develop new superior drugs using Sirona’s innovative platform technology; exploring partnership opportunities with companies that have expressed interest in licensing our SGLT2 inhibitor for type 2 diabetes in markets outside of China (i.e. US, Russia, India) and finding partnerships to assist building the glycoprotein project pipeline.
“We remain focused on advancing our partnering discussions for our skin lightener SBM-TFC-1067, while we are continually expanding our product pipeline,” said Attila Hajdu, Chief Business Development Officer of Sirona Biochem.
“Bioavailability and toxicity are the main reasons clinical programs fail in the current pharmaceutical environment, and we have a solution for this problem. That’s why we see a strong interest from big pharma in the application of our fluorine chemistry platform across multiple target programs to drive future growth,” he added.
BIO-Europe® is the EBD Group’s flagship conference, and the premier Spring partnering conference for the biotech industry. It is attended by the most significant global corporations and provides life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at www.ebdgroup.com/bes.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Target Price for Sirona Biochem (SBM:tsxv) 0.98$
Sirona Biochem (SBM:tsxv) Gets BUY Rating : Target Price CAD 0.98$
– Momentum Public Relations –
Yesterday, First Berlin Equity Research published a research update on Sirona Biochem Corp. (SBM:tsxv). Analyst Ellis Acklin reiterated his BUY rating and increased the price target from CAD 0.90 to CAD 0.98.
This is an abbreviated summary. The full text of this story (including disclosure) is included below.
Abstract:
Sirona Biochem Corp. (Sirona) published annual results for the year ended 31 October 2015. Results were largely in line with our forecasts. The company continues to communicate confidence in the signing of a new agreement for its promising skin lightening treatment TFC-1067. We see this as a potential watershed event for the company. Potential upfront, milestone and royalty payments harbour significant upside for Sirona once a deal is sealed. After recalibrating our forecasts and model, we raise our price target to C$0.98 (previously: C$0.90) and reiterate our Buy rating.
Financial Forecasts: |
2013 |
2014 |
2015 |
2016E |
2017E |
2018E |
Revenue (CADm) |
0.00 |
0.21 |
0.01 |
0.38 |
8.79 |
21.45 |
EBIT (CADm) |
-2.64 |
-3.48 |
-3.48 |
-3.20 |
5.13 |
17.69 |
EPS (diluted) (CAD) |
-0.03 |
-0.03 |
-0.03 |
-0.01 |
0.02 |
0.07 |
FCF (CADm) |
-2.62 |
-2.09 |
-3.18 |
-2.88 |
2.76 |
10.88 |
http://www.slideshare.net/MomentumPR/first-berlin-equity-research-sbmtsxv
- Published in Blog, Life Sciences, Sirona Biochem
Sirona Presented at the Dose of the Valley Conference
Sirona Biochem attends the Dose of the Valley Conference, San Francisco
– Momentum Public Relations –
Sirona Biochem (SBM:tsxv), an emerging biochemistry company based in Vancouver, B.C., was invited for the second time by the consulate general of Canada in San Francisco to present at the annual Dose of the Valley Conference. The invite-only event took place on February 9-10, 2016 in San Francisco, California.
Sirona Biochem had the unique opportunity to showcase its proprietary platform technology, as well as its diabetes and anti-aging assets to international key players to the likes of l’Oreal, Merck and Johnson & Johnson. During the event, they participated in facilitated meetings, follow up discussions and received feedback from investors. Most importantly, the exclusive event offered many potential partnering opportunities.
Needless to say, this was a cruicial event for Sirona Biochem as their products could bring value to big pharma companies around the world. “Sirona has an innovative platform technology that can be applied to develop new compounds in areas of unmet needs, and we have already begun to explore strategic partnerships with big pharma to unlock the potential value in new opportunities,” said Attila Hajdu, Sirona Biochem’s Chief Business Development Officer, prior to the conference.
Dose of the Valley Conference, San Francisco
The Dose of the Valley conference is a two-day event put together by the C100, BDC Venture Capital, and the Consulate General of Canada in San Francisco. The prestigious event offers the exclusive opportunity to connect a select few of Canada’s most promising life science companies from the biopharmaceutical, medical device and health IT sectors with key players in the Bay Area and Silicon Valley.
San Francisco and more specifically, Silicon Valley is an international hub for flourishing companies in the life sciences sector. A large handful of pharmaceutical companies, medical providers, venture capital, and technology companies have settled in the region, which holds infinite opportunities for Canadian companies such as Sirona Biochem. “The criteria for selection were evaluated on stage of development and industry validation, so we are excited to participate in such a focused event,” added Hajdu. In addition, applications to attend were based on relevancy to industry interests. A few other companies selected to attend were Zucara Therapeutics and the Commercialization for Research Institute in Immunology and Cancer (IRICoR).
The Dose of the Valley Conference was held on February 9-10 in San Francisco, California, and facilitated face-to-face meetings with potential investors, technology scouts, mentors and other industry experts. In attending, Sirona Biochem hoped to gain visibility and develop new partnerships. Sirona’s Chief Business Development Officer Attila Hajdu presented the Company’s pipeline and future strategy at the conference. Hajdu also participated in follow up meetings with key investors and leading companies in the pharmaceutical and cosmetic industries.
About Sirona Biochem
Founded in 2009, Sirona Biochem is a Vancouver based ingredient and drug discovery company dealing with proprietary innovative platform technology of fluorination chemistry. In 2011, the company acquired TF Chem for their chemistry technology and expertise. They develop safer, more effective cosmetic and pharmaceutical active ingredients that are licensed to various partners in exchange for upfront milestone and royalty payments.
The company has recently made headlines as they are currently in discussions with five of the largest pharmaceutical companies in the world about licensing their new skin-lightening technology. This represents a major deal for Sirona, which has a market cap of just over $30 million. For additional information visit www.sironabiochem.com, we have also included their corporate video presentation below.
- Published in Blog, Sirona Biochem
Sirona Biochem: The Leader in Carbohydrate Stabilization Technology
Sirona Biochem: The Global Leader in Carbohydrate Stabilization Technology
– Momentum Public Relations –
Sirona Biochem (SBM:tsxv) is a proactive development and discovery stage based biotech firm with an R&D lab situated in Paris, France. The biotechnology enterprise is headquartered in Vancouver, British Columbia in Canada, and is world renowned for its state of the art fluorination chemistry technology. Their cutting edge platform is currently used to create cosmetic products that are both safe and effective for human use and consumption, as well as a plethora of pharmaceutical drugs.
Moreover, their leading edge compounds are either acquired by or licensed by multinational conglomerates in return for royalties, milestone payments, and/or marked upfront payments. It should also be noted that their platform focuses on the molecular stabilization of carbohydrates; which is noteworthy because carbohydrate based drugs are one of the most commonly prescribed drug families in the United States. De facto, some of the most commonly prescribed carbohydrate based drugs in the United States include Abbott’s Biaxin, Pfizer’s Zithromax, and GlaxoSmithKline’s Lanoxin.
In addition, Sirona Biochem currently has two licensing agreements with two multibillion dollar companies; namely Valeant Pharmaceuticals International (VRX:tsx) and Wanbang Biopharma. Valeant was founded in 1960 in Laval, Quebec, Canada and generated revenues of 2.73 billion U.S. in Q2 of 2015. What’s more, Valeant recently licensed a safe and innovative skin lightener, with Sirona Biochem to reap several millions in royalties in the near future from the licensing deal.
As for Wanbang Biopharma, the company was founded in China in 1998 and is a part of Fosun International (9.4 billion in U.S. revenue). The corporation focuses on the development of pharmaceutical drugs used to treat diabetes and associated cardiovascular diseases. Wanbang Biopharma also recently acquired the exclusive rights to sell the SGLT2 inhibitor that Sirona Biochem developed to treat type 2 diabetes. With the exclusive rights, Wanbang Biopharma will be able to sell the inhibitor in the People’s Republic of China, with $9.5 million in U.S. payments being awarded to Sirona Biochem in the form of milestone and upfront payments; with a percentage of total sales also being awarded to the pharmaceutical company in the form of perpetual royalties.
In regards to the skin lightening market, it is currently focused in the Asian Pacific regions and Japan, with the booming market expected to generate over 20 billion U.S. in revenue by 2018; with an annual growth rate projected at 25{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. However, many of the skin lightening products currently being sold globally contain malevolent compounds; including DeoxyArbutin, Arbutin, and Hydroquinone. Due to the controversy and health concerns surrounding the aforementioned skin lightener compounds products containing these compounds are strictly regulated and even outright banned in certain countries.
Fortunately, Sirona Biochem has created a safe alternative compound known as TFC-1067 to resolve these issues. TFC-1067 is not only safe but also boasts 8 times the efficacy of DeoxyArbutin. Given the numerous benefits that TFC-1067 provides over its competitors, multinational cosmetic conglomerates like Proctor and Gamble, Allergan, L’Oreal, and Amore Pacific Corporation with marketed skin lighteners are interested in Sirona’s leading edge compound.
Industry analysts have predicted that the global anti-aging market is expected to reach nearly $300 billion by 2015. Interestingly, Sirona is developing unique regenerative compounds based on research conducted by Professor Arthur DeVrie in the late 1960s. Essentially, his research found that the reason why Antarctic fish were able to survive in harsh, subzero temperatures was due to blood serum glycoproteins. Inspired by Professor Arthur DeVrie’s monumental discovery, Sirona Biochem is currently producing a family of regenerative, anti-aging, and naturally occurring compounds that are based on the antifreeze and anti-aging glycoproteins
Furthermore, in vitro studies have shown that these glycoproteins have a protective effect in fibroblasts against a myriad of stresses caused by nutrient depravation, oxidation, and UV light; all of which contribute to the visible signs of aging.
As Sirona Biochem continues to work diligently to harness the full protective and restorative properties of these glycoproteins the company is currently looking to collaborate with several global multinationals to further characterize and develop these glycoproteins for a myriad of commercial applications. In addition, their early stage partnerships with many prominent entities will allow Sirona Biochem to provide added value to their shareholders by maximizing their ROI. Another benefit of their ongoing projects is that they have a very short time to approval; with FDA approvals not being required.
If you would like to learn more about the world leader in carbohydrate chemistry commercialization please visit here.
- Published in Blog, Life Sciences, Sirona Biochem
Sirona Biochem (SBM:) Invited to Present at the Dose of the Valley Conference
Sirona Biochem (SBM:V) Invited to Present at Dose of the Valley Conference, San Francisco
Momentum Public Relations – Jan. 25, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 – 10 in San Francisco, California.
Sirona’s Chief Business Development Officer, Attila Hajdu, will communicate the current state of the Company’s pipeline and future strategy in addition to participating in follow up meetings with key investors and leading companies in the pharmaceutical and cosmetic industries. The Canadian Technology Accelerator program is a new conference feature this year that identifies areas of potential collaboration for Sirona’s platform technology of fluorination chemistry.
“We are extremely happy to be invited back to the Dose of the Valley and look forward to exploring new growth opportunities,” said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “Sirona has an innovative platform technology that can be applied to develop new compounds in areas of unmet needs, and we have already begun to explore strategic partnerships with big pharma to unlock the potential value in new opportunities.”
About Dose of the Valley
The two-day program organized by the C100 (www.thec100.org), BDC Venture Capital (www.bdc.ca) and the San Francisco Consulate is designed to connect Canada’s most promising biopharma, medical device, and health IT companies with key players from within the Bay Area and Silicon Valley. Dose of the Valley will facilitate face-to-face interaction with investors, technology scouts, mentors, and industry experts. The program provides an opportunity to gain visibility and develop productive relationships within this vibrant ecosystem.
San Francisco and the Silicon Valley represent a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. Applications for participation will be evaluated based on stage of development, industry validation, and relevancy to local industry interests. Elements of this program will be built to reflect the corporate objectives and therapeutic focus of participating companies.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem
Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins
Vancouver, British Columbia – November 3, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB), (the “Company”) is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason’s role will be primarily to provide strategic advice and an action plan for the Company’s glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.
Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere®, which was sold to BTG for $200 million.
Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.
“I look forward to working closely with management on the glycoprotein project over the next few months,” said Dr. Mason Ross. “I can’t think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous.”
“We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener,” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Biochem Presents New Results from Glycoprotein Program at BIO-Europe
Vancouver, British Columbia – October 26, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB) (the “Company”) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany.
New results from the glycoprotein program for anti-aging and regenerative medicine will be presented, including positive efficacy data and potential new collaborative projects with cosmetic companies.
The conference is attended by major multinational pharmaceutical corporations and provides further opportunities to engage leading companies in partnering discussions for the newest skin-lightener, SBM-TFC-1067 (1067) and the glycoprotein compounds SBM-TFC-837,1165 and 1287.
“Clearly, we have significantly progressed partnering discussions for 1067 with a select group of companies that have been testing our compound since June, including formulation testing,” said Attila Hajdu. “This conference provides an opportunity to broaden the base of companies interested in licensing 1067. We were very excited about the interest from several new companies following Cosmetic 360 in Paris.”
Major companies attending the conference include Allergan, GSK, JT Pharma, Pfizer and many others.
BIO-Europe® is the EBD Group’s flagship conference, and continues the tradition of providing life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at http://www.ebdgroup.com/bes.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Announces Warrants Exercised
Vancouver, British Columbia – September 28, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt/Xetra®: ZSB), (the “Company”) is pleased to announce that it has generated a total of $1,024,328 as a result of share purchase warrant exercises of 6,120,800 shares and the share purchase option exercise of 300,000 shares over the past week. The warrants had an expiry date of September 19, 2015.
“This cash injection provides the necessary funding for the Company until completion of a licensing deal with SBM-TFC-1067,” said Dr. Howard Verrico, CEO and Chairman of Sirona.
Net proceeds from the warrants exercised will be used to finance Sirona’s cosmeceutical and therapeutic programs utilizing the Company’s innovative platform technology, as well as for general corporate purposes.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem
Sirona Biochem Reaches Major Milestone by Successful Scale-Up of Skin Lightening Compound SBM-TFC-1067
Vancouver, British Columbia – September 15, 2015 – Sirona Biochem Corp. (TSX-V: SBM, Frankfurt: ZSB, Xetra®: ZSB.DE) (the “Company”) is pleased to announce the successful scale-up of its skin lightening compound SBM-TFC-1067 (“1067”).
Sirona Biochem commissioned its contract research organization (CRO) Roowin (www.roowin.com) for the scale-up of 1 kg of 1067 compound. The successful scale-up represents a major scientific breakthrough by Sirona’s laboratory in Rouen, France. A quantity of 200 grams of 1067 was delivered last week for formulation and solubility testing by a major multinational corporation under a previously signed material transfer agreement.
One of the major differentiators between 1067 and Sirona’s earlier generation skin lightening compounds is that the chemical process of applying Sirona’s proprietary fluorination technology now requires only three steps to yield a final product. This results in a highly favourable cost of goods (COGs) and more importantly, a product with very profitable commercial viability. A preliminary estimation of COGs for the active ingredient yielded $0.10 CAD per 100 ml final formulation at a final concentration of 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}.
Dr. Howard Verrico, CEO of Sirona Biochem, states, “Formulation testing on this quantity of compound represents a major milestone in the development of 1067, which will ultimately result in a successful licensing deal with one of the top cosmetic companies in the world.” He further stated, “This is the first time in Sirona’s history that we have advanced a cosmetic compound to formulation testing.”
Attila Hajdu, Chief Business Development Officer at Sirona Biochem, said, “Potential partners have replicated in vitro tests that we have done in the past to double-check our efficacy and safety data, and whatever else meets their needs to justify further collaboration. The request for formulation testing was a pleasant surprise for us because we originally anticipated that formulation work would occur after a licensing deal. This is a very exciting development.”
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Sirona Biochem